Eiko Yamakawa P, Perez Gomes C, Ribeiro Mendes A, Cesar Justino de Oliveira C, Porto Freitas F, Bettoni F
Front Med (Lausanne). 2025; 12:1472186.
PMID: 40066167
PMC: 11891177.
DOI: 10.3389/fmed.2025.1472186.
Sampei Z, Haraya K, Gan S, Muraoka M, Hayasaka A, Fukuzawa T
Int J Mol Sci. 2024; 25(21).
PMID: 39519232
PMC: 11546984.
DOI: 10.3390/ijms252111679.
Hillmen P, Horneff R, Yeh M, Kolev M, Deschatelets P
Int J Mol Sci. 2024; 25(17).
PMID: 39273426
PMC: 11395449.
DOI: 10.3390/ijms25179477.
Wang P, Jiang W, Lai T, Liu Q, Shen Y, Ye B
Haematologica. 2024; 109(9):2778-2789.
PMID: 38988263
PMC: 11367197.
DOI: 10.3324/haematol.2023.284312.
Mulherin B, Yeh M, Al-Adhami M, Dingli D
Drugs R D. 2024; 24(2):169-177.
PMID: 38727860
PMC: 11315842.
DOI: 10.1007/s40268-024-00463-9.
Erythrocyte PIG-A mutant frequencies in cancer patients receiving cisplatin.
Dobrovolsky V, Atiq O, Heflich R, Maisha M, McKinzie P, Pearce M
Cancer Med. 2024; 13(3):e6895.
PMID: 38214136
PMC: 10905239.
DOI: 10.1002/cam4.6895.
A review of the treatment landscape in paroxysmal nocturnal haemoglobinuria: where are we now and where are we going?.
Griffin M, Kelly R, Pike A
Ther Adv Rare Dis. 2023; 1:2633004020959349.
PMID: 37180495
PMC: 10032435.
DOI: 10.1177/2633004020959349.
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.
Wong R, Navarro-Cabrera J, Comia N, Goh Y, Idrobo H, Kongkabpan D
Blood Adv. 2023; 7(11):2468-2478.
PMID: 36848639
PMC: 10241857.
DOI: 10.1182/bloodadvances.2022009129.
The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano A, Frieri C, Urciuoli E, Marano L
Immunol Rev. 2022; 313(1):262-278.
PMID: 36110036
PMC: 10087358.
DOI: 10.1111/imr.13137.
Safety and efficacy of pegcetacoplan in paroxysmal nocturnal hemoglobinuria.
Wong R
Ther Adv Hematol. 2022; 13:20406207221114673.
PMID: 35923770
PMC: 9340389.
DOI: 10.1177/20406207221114673.
Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
Wong R, Pullon H, Amine I, Bogdanovic A, Deschatelets P, Francois C
Ann Hematol. 2022; 101(9):1971-1986.
PMID: 35869170
PMC: 9375762.
DOI: 10.1007/s00277-022-04903-x.
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria.
Kulasekararaj A, Brodsky R, Nishimura J, Patriquin C, Schrezenmeier H
Ther Adv Hematol. 2022; 13:20406207221091046.
PMID: 35663504
PMC: 9160915.
DOI: 10.1177/20406207221091046.
Insights Into the Emergence of Paroxysmal Nocturnal Hemoglobinuria.
Colden M, Kumar S, Munkhbileg B, Babushok D
Front Immunol. 2022; 12:830172.
PMID: 35154088
PMC: 8831232.
DOI: 10.3389/fimmu.2021.830172.
A Pig-a conditional knock-out mice model mediated by Vav-iCre: stable GPI-deficient and mild hemolysis.
Chen Y, Liu H, Zeng L, Li L, Lu D, Liu Z
Exp Hematol Oncol. 2022; 11(1):1.
PMID: 35033195
PMC: 8760646.
DOI: 10.1186/s40164-022-00254-5.
The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
Dingli D, Matos J, Lehrhaupt K, Krishnan S, Yeh M, Fishman J
Ann Hematol. 2022; 101(2):251-263.
PMID: 34973099
PMC: 8720163.
DOI: 10.1007/s00277-021-04715-5.
Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway.
Barratt J, Weitz I
Front Immunol. 2021; 12:712572.
PMID: 34566967
PMC: 8458797.
DOI: 10.3389/fimmu.2021.712572.
How we('ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future.
Risitano A, Peffault de Latour R
Br J Haematol. 2021; 196(2):288-303.
PMID: 34355382
PMC: 9291300.
DOI: 10.1111/bjh.17753.
Assessment of the gene mosaicism burden in blood and its implications for immune disorders.
Solis-Moruno M, Mensa-Vilaro A, Batlle-Maso L, Lobon I, Bonet N, Marques-Bonet T
Sci Rep. 2021; 11(1):12940.
PMID: 34155260
PMC: 8217568.
DOI: 10.1038/s41598-021-92381-y.
C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab.
de Castro C, Grossi F, Weitz I, Maciejewski J, Sharma V, Roman E
Am J Hematol. 2021; 95(11):1334-1343.
PMID: 33464651
PMC: 7693064.
DOI: 10.1002/ajh.25960.
Paroxysmal nocturnal haemoglobinuria associated with a novel phosphatidylinositol glycan class A (PIGA) mutation in a patient with Klinefelter syndrome.
Tamai Y, Ito S, Hasegawa A
Ann Hematol. 2021; 100(6):1625-1627.
PMID: 33416903
DOI: 10.1007/s00277-020-04377-9.